ROCHESTER, Minn.--(BUSINESS WIRE)--RION, a clinical-stage regenerative medicine company at the forefront of exosome-based therapeutics, today announced the enrollment of the first patient in its Phase ...
Lonza agreed to provide cGMP manufacturing and technical support for commercial scale production of RION’s Purified Exosome Product™ (PEP) drug substance for late phase clinical supply and beyond.
RION, a clinical-stage regenerative medicine company and global leader in exosome-based therapeutics, today announced the formation of RION Vet, a veterinary biotechnology company advancing a ...
Rion, founded in Rochester in 2017, plans to build a new manufacturing facility in a 10,000-square-foot space in Building 103 on the Rochester Technology Campus by the end of 2024 or early in 2025.
ROCHESTER — Rion, Mayo Clinic and the U.S. Army Medical Research Institute for Chemical Defense will use a $2.4 million grant from the U.S. Department of Defense to research treatments for soldiers ...
Lonza to support cGMP manufacturing of RION’s Purified Exosome Product™ (PEP™), a platelet-derived exosome-based drug candidate for chronic wound care and tissue regeneration Collaboration leverages ...
RION LAUNCHES RION VET TO TRANSFORM ANIMAL HEALTH WITH FIRST-IN-CLASS BIOLOGIC THERAPEUTIC; APPOINTS INDUSTRY LEADER MARK HERTHEL AS CEO; ANNOUNCES SERIES A FULFILLMENT RION, a clinical-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results